Drug Discovery Platform
PolyMedix was formed in 2002 after receiving worldwide exclusive licenses to a computational drug design technology (CDDT) that was developed at the University of Pennsylvania by Drs. William DeGrado, Michael Klein, and Gregory Tew, and a series of patent applications covering the composition and use of core compounds originating from the CDDT. PolyMedix has continued the development of this technology using targeted design and medicinal chemistry approaches to understand the intricate relationships between molecular structure and activity of compounds and to produce potent drugs that lack detrimental side-effects.
The scope and breadth of PolyMedix’s technology platform in identifying and designing fully synthetic, nonpeptidic small molecules that mimic proteins and disrupt protein interactions has been captured through creation of:
- PMX-30063 antibiotic which is a small molecule that mimics host defense proteins and disrupts the target membrane of bacteria.
- PMX-60056 heptagonist which mimics a blood coagulation factor and disrupts interactions with the polysaccharides, heparin and low molecular weight heparin.
- 65% of all compounds have been biologically active (“hits”)
- 40% have been potent and selective (“leads”)
